Multi-drug resistance in chronic lymphocytic leukemia

William R. Friedenberg, Susan K. Spencer, Cynthia Musser, Thomas F. Hogan, Keith A. Rodvold, Daniel A. Rushing, Joseph J. Mazza, Duane A. Tewksbury, James J. Marx

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We evaluated 45 chronic lymphocyte leukemia (CLL) patients for the presence of multi-drug resistance (MDR by the ex vivo techniques: 1) a functional assay utilizing doxorubicin (dox) retention with modulation; 2) a cytotoxicity assay (MTT) with modulation; 3) and four monoclonal antibodies. Ex vivo tests were correlated with disease stage and prior treatment, and were repeated as patients became resistant to alkylating agents, fludarabine and VAD chemotherapy (infusion of vincristine, dox, and oral dexamethasone). The majority of patients (64.4%) were in early stage and were untreated (62.2%). P-glycoprotein (p-gp 170) was detected most frequently by the monoclonal antibody MRK 16 (48%) and by functional modulation of dox retention by PSC-833 (40.6%) and by functional modulation of the MTT assay with vincristine (0.29) and dox (0.39) with PSC-833 at 1.0 μg/mL. Functional modulation of dox retention with PSC-833 was significantly associated with stage, but not with either the MTT assay or any of the monoclonal antibodies. None of the tests correlated with prior chlorambucil treatment. Correlation of dox retention with the monoclonal antibodies was mild to moderate and became stronger following chlorambucil treatment. Three patients who became resistant to VAD were found to express p-gp 170. We conclude that MDR can frequently be detected in patients with CLL. Furthermore, the expression of p-gp 170 increases with advancing stage, but not prior alkylating agent therapy. The functional expression of p-gp 170 increases with advancing stage and prior treatment and correlates well with monoclonal antibody detection (especially MRK-16). Patients who become resistant to VAD more frequently express p-gp 170 by a variety of techniques, PSC-833 is a more potent modulator of MDR than cyclosporin-A (CsA) ex vivo, and correlates better with stage of disease.

Original languageEnglish (US)
Pages (from-to)171-178
Number of pages8
JournalLeukemia and Lymphoma
Volume34
Issue number1-2
StatePublished - 1999
Externally publishedYes

Fingerprint

Multiple Drug Resistance
B-Cell Chronic Lymphocytic Leukemia
Doxorubicin
Monoclonal Antibodies
Chlorambucil
Alkylating Agents
Vincristine
Leukemia
Lymphocytes
Therapeutics
P-Glycoprotein
Dexamethasone
Cyclosporine
Drug Therapy
valspodar

Keywords

  • Chronic lymphocytic leukemia
  • Multi-drug resistance
  • P-gp 170 (p-glycoprotein)
  • PSC-833

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Friedenberg, W. R., Spencer, S. K., Musser, C., Hogan, T. F., Rodvold, K. A., Rushing, D. A., ... Marx, J. J. (1999). Multi-drug resistance in chronic lymphocytic leukemia. Leukemia and Lymphoma, 34(1-2), 171-178.

Multi-drug resistance in chronic lymphocytic leukemia. / Friedenberg, William R.; Spencer, Susan K.; Musser, Cynthia; Hogan, Thomas F.; Rodvold, Keith A.; Rushing, Daniel A.; Mazza, Joseph J.; Tewksbury, Duane A.; Marx, James J.

In: Leukemia and Lymphoma, Vol. 34, No. 1-2, 1999, p. 171-178.

Research output: Contribution to journalArticle

Friedenberg, WR, Spencer, SK, Musser, C, Hogan, TF, Rodvold, KA, Rushing, DA, Mazza, JJ, Tewksbury, DA & Marx, JJ 1999, 'Multi-drug resistance in chronic lymphocytic leukemia', Leukemia and Lymphoma, vol. 34, no. 1-2, pp. 171-178.
Friedenberg WR, Spencer SK, Musser C, Hogan TF, Rodvold KA, Rushing DA et al. Multi-drug resistance in chronic lymphocytic leukemia. Leukemia and Lymphoma. 1999;34(1-2):171-178.
Friedenberg, William R. ; Spencer, Susan K. ; Musser, Cynthia ; Hogan, Thomas F. ; Rodvold, Keith A. ; Rushing, Daniel A. ; Mazza, Joseph J. ; Tewksbury, Duane A. ; Marx, James J. / Multi-drug resistance in chronic lymphocytic leukemia. In: Leukemia and Lymphoma. 1999 ; Vol. 34, No. 1-2. pp. 171-178.
@article{cad2ae64d6044dfbaab423bc88faa3c5,
title = "Multi-drug resistance in chronic lymphocytic leukemia",
abstract = "We evaluated 45 chronic lymphocyte leukemia (CLL) patients for the presence of multi-drug resistance (MDR by the ex vivo techniques: 1) a functional assay utilizing doxorubicin (dox) retention with modulation; 2) a cytotoxicity assay (MTT) with modulation; 3) and four monoclonal antibodies. Ex vivo tests were correlated with disease stage and prior treatment, and were repeated as patients became resistant to alkylating agents, fludarabine and VAD chemotherapy (infusion of vincristine, dox, and oral dexamethasone). The majority of patients (64.4{\%}) were in early stage and were untreated (62.2{\%}). P-glycoprotein (p-gp 170) was detected most frequently by the monoclonal antibody MRK 16 (48{\%}) and by functional modulation of dox retention by PSC-833 (40.6{\%}) and by functional modulation of the MTT assay with vincristine (0.29) and dox (0.39) with PSC-833 at 1.0 μg/mL. Functional modulation of dox retention with PSC-833 was significantly associated with stage, but not with either the MTT assay or any of the monoclonal antibodies. None of the tests correlated with prior chlorambucil treatment. Correlation of dox retention with the monoclonal antibodies was mild to moderate and became stronger following chlorambucil treatment. Three patients who became resistant to VAD were found to express p-gp 170. We conclude that MDR can frequently be detected in patients with CLL. Furthermore, the expression of p-gp 170 increases with advancing stage, but not prior alkylating agent therapy. The functional expression of p-gp 170 increases with advancing stage and prior treatment and correlates well with monoclonal antibody detection (especially MRK-16). Patients who become resistant to VAD more frequently express p-gp 170 by a variety of techniques, PSC-833 is a more potent modulator of MDR than cyclosporin-A (CsA) ex vivo, and correlates better with stage of disease.",
keywords = "Chronic lymphocytic leukemia, Multi-drug resistance, P-gp 170 (p-glycoprotein), PSC-833",
author = "Friedenberg, {William R.} and Spencer, {Susan K.} and Cynthia Musser and Hogan, {Thomas F.} and Rodvold, {Keith A.} and Rushing, {Daniel A.} and Mazza, {Joseph J.} and Tewksbury, {Duane A.} and Marx, {James J.}",
year = "1999",
language = "English (US)",
volume = "34",
pages = "171--178",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Multi-drug resistance in chronic lymphocytic leukemia

AU - Friedenberg, William R.

AU - Spencer, Susan K.

AU - Musser, Cynthia

AU - Hogan, Thomas F.

AU - Rodvold, Keith A.

AU - Rushing, Daniel A.

AU - Mazza, Joseph J.

AU - Tewksbury, Duane A.

AU - Marx, James J.

PY - 1999

Y1 - 1999

N2 - We evaluated 45 chronic lymphocyte leukemia (CLL) patients for the presence of multi-drug resistance (MDR by the ex vivo techniques: 1) a functional assay utilizing doxorubicin (dox) retention with modulation; 2) a cytotoxicity assay (MTT) with modulation; 3) and four monoclonal antibodies. Ex vivo tests were correlated with disease stage and prior treatment, and were repeated as patients became resistant to alkylating agents, fludarabine and VAD chemotherapy (infusion of vincristine, dox, and oral dexamethasone). The majority of patients (64.4%) were in early stage and were untreated (62.2%). P-glycoprotein (p-gp 170) was detected most frequently by the monoclonal antibody MRK 16 (48%) and by functional modulation of dox retention by PSC-833 (40.6%) and by functional modulation of the MTT assay with vincristine (0.29) and dox (0.39) with PSC-833 at 1.0 μg/mL. Functional modulation of dox retention with PSC-833 was significantly associated with stage, but not with either the MTT assay or any of the monoclonal antibodies. None of the tests correlated with prior chlorambucil treatment. Correlation of dox retention with the monoclonal antibodies was mild to moderate and became stronger following chlorambucil treatment. Three patients who became resistant to VAD were found to express p-gp 170. We conclude that MDR can frequently be detected in patients with CLL. Furthermore, the expression of p-gp 170 increases with advancing stage, but not prior alkylating agent therapy. The functional expression of p-gp 170 increases with advancing stage and prior treatment and correlates well with monoclonal antibody detection (especially MRK-16). Patients who become resistant to VAD more frequently express p-gp 170 by a variety of techniques, PSC-833 is a more potent modulator of MDR than cyclosporin-A (CsA) ex vivo, and correlates better with stage of disease.

AB - We evaluated 45 chronic lymphocyte leukemia (CLL) patients for the presence of multi-drug resistance (MDR by the ex vivo techniques: 1) a functional assay utilizing doxorubicin (dox) retention with modulation; 2) a cytotoxicity assay (MTT) with modulation; 3) and four monoclonal antibodies. Ex vivo tests were correlated with disease stage and prior treatment, and were repeated as patients became resistant to alkylating agents, fludarabine and VAD chemotherapy (infusion of vincristine, dox, and oral dexamethasone). The majority of patients (64.4%) were in early stage and were untreated (62.2%). P-glycoprotein (p-gp 170) was detected most frequently by the monoclonal antibody MRK 16 (48%) and by functional modulation of dox retention by PSC-833 (40.6%) and by functional modulation of the MTT assay with vincristine (0.29) and dox (0.39) with PSC-833 at 1.0 μg/mL. Functional modulation of dox retention with PSC-833 was significantly associated with stage, but not with either the MTT assay or any of the monoclonal antibodies. None of the tests correlated with prior chlorambucil treatment. Correlation of dox retention with the monoclonal antibodies was mild to moderate and became stronger following chlorambucil treatment. Three patients who became resistant to VAD were found to express p-gp 170. We conclude that MDR can frequently be detected in patients with CLL. Furthermore, the expression of p-gp 170 increases with advancing stage, but not prior alkylating agent therapy. The functional expression of p-gp 170 increases with advancing stage and prior treatment and correlates well with monoclonal antibody detection (especially MRK-16). Patients who become resistant to VAD more frequently express p-gp 170 by a variety of techniques, PSC-833 is a more potent modulator of MDR than cyclosporin-A (CsA) ex vivo, and correlates better with stage of disease.

KW - Chronic lymphocytic leukemia

KW - Multi-drug resistance

KW - P-gp 170 (p-glycoprotein)

KW - PSC-833

UR - http://www.scopus.com/inward/record.url?scp=0033036047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033036047&partnerID=8YFLogxK

M3 - Article

C2 - 10350346

AN - SCOPUS:0033036047

VL - 34

SP - 171

EP - 178

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -